Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?
In this clinical pilot study, the influence of heparin pretreatment on the haemostatic system during and after cardiopulmonary bypass (CPB) was investigated. Thirteen patients scheduled for elective coronary artery bypass grafting (CABG) were divided into two groups: heparin pretreated (HP, n = 6) and non-heparin pretreated (NHP, n = 7). Blood samples were taken for measurements of plasma antithrombin-III (AT-III) activity, plasma heparin levels, activated clotting time with (HACT) and without (ACT) heparinase, whole blood platelet function, platelet count, thrombin-antithrombin-III complexes and D-dimer levels. Also, the mediastinal blood loss within the initial 20 h after surgery, and the blood transfusion requirements were monitored. The mean duration of the heparin pretreatment was 55 h (range 24-161 h). There was no significant difference in plasma AT-III activity and platelet count between the groups. Before and after CPB, the platelet responsiveness was better in the NHP group (p < 0.05). The HACT was prolonged in the NHP group during and after CPB compared to baseline values (p < 0.05), whereas, in the HP group, no significant changes were found. Plasma heparin levels and ACT values suggested adequate anticoagulation during CPB. However, the extent of thrombin inhibition and fibrinolysis increased with time on CPB, but did not differ between the two groups. Twenty hours after surgery, the thrombin inhibition showed to be significantly higher in the NHP group. Furthermore, mediastinal blood loss showed a tendency to be lower in the HP group (p = 0.08). However, there was no difference in blood transfusion requirements between the groups. These data suggest that short-term heparin pretreatment affects the perioperative platelet responsiveness and attenuates the consumption of coagulation factors.
Brinks
H J
HJ
Department of Extracorporeal Circulation, University Medical Centre St. Radboud, Nijmegen.
Weerwind
P W
PW
Bogdan
S
S
Verbruggen
H
H
Brouwer
M H
MH
D000368:Aged; D000925:Anticoagulants / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D000990:Antithrombin III / Q000032:analysis; D001780:Blood Coagulation Tests; D016063:Blood Loss, Surgical; D001803:Blood Transfusion / Q000706:statistics & numerical data; D002315:Cardiopulmonary Bypass; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control; D004351:Drug Resistance; D017558:Elective Surgical Procedures; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D019763:Heparin Lyase / Q000494:pharmacology; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control; D007432:Intraoperative Period; D008297:Male; D008482:Mediastinum / Q000098:blood supply; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D010865:Pilot Projects; D010976:Platelet Count; D010979:Platelet Function Tests; D011183:Postoperative Complications / Q000517:prevention & control; D011184:Postoperative Period; D011229:Preanesthetic Medication; D013921:Thrombocytopenia / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control; D016896:Treatment Outcome
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D019763:Heparin Lyase